Evidence map›Paper›PMID 36320198›Full record

ArticleOpen forum infectious diseases2022

Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study.

Cas Isfordink, Anders Boyd, Amanda Mocroft, Katharina Kusejko, Colette Smit, Stephane de Wit, Tabitha Mahungu, Karolin Falconer, Gilles Wandeler, Matthias Cavassini and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Cas IsfordinkDivision of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0003-0999-2336
Anders BoydStichting HIV Monitoring, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0001-9512-8928
Amanda MocroftCentre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-8316-1122
Katharina KusejkoDepartment of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.ORCID https://orcid.org/0000-0002-4638-1940
Colette SmitStichting HIV Monitoring, Amsterdam, The Netherlands.
Stephane de WitDivision of Infectious Diseases, St Pierre Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Tabitha MahunguDepartment of Infectious Diseases, Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Karolin FalconerDepartment of Infectious Diseases/Venhälsan, Södersjukhuset, Stockholm, Sweden.
Gilles WandelerDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Matthias CavassiniDivision of Infectious Diseases, Lausanne University Hospital, University of Lausanne, Lausanne, Switzerland.ORCID https://orcid.org/0000-0003-0933-7833
Marcel StöckleDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, University of Basel, Basel, Switzerland.
Janke SchinkelSection of Clinical Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Andri RauchDepartment of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Lars PetersCentre of Excellence for Health, Immunity and Infections, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Marc van der ValkDivision of Infectious Diseases, Department of Internal Medicine, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
for EuroSIDA, the Swiss HIV Cohort Study, and the ATHENA Observational Cohort

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)/HCV from SSA or SEA residing in Europe is unknown. Methods: We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result ≥12 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR Results: Of the 3293 individuals with HIV/HCV treated with DAA and with available SVR Conclusions: SVR

Indexed as

coinfectioneliminationhepatitis C virushuman immunodeficiency virus

Identifiers

PMID36320198
PMCPMC9605702

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.